Salud financiera de hoja de balance de Pulmatrix

Salud financiera controles de criterios 6/6

Pulmatrix tiene un patrimonio de los accionistas total de $18.0M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $34.0M y $16.0M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$19.17m
Patrimonio	US$18.00m
Total pasivo	US$15.96m
Activos totales	US$33.96m

Actualizaciones recientes sobre salud financiera

Recent updates

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

Jul 12

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Feb 22

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Oct 29

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Aug 16

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 14

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

May 27

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Feb 11

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($20.8M) de PULM superan a sus pasivos a corto plazo ($3.9M).

Pasivo a largo plazo: Los activos a corto plazo de PULM ($20.8M) superan a sus pasivos a largo plazo ($12.1M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: PULM está libre de deudas.

Reducción de la deuda: PULM no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: PULM tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: PULM dispone de suficiente cash runway para 1.1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 12.1% cada año.

Salud financiera de hoja de balance de Pulmatrix

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Pulmatrix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Recent updates

Full year 2023 earnings released: US$3.87 loss per share (vs US$5.46 loss in FY 2022)

Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis

Insufficient new directors

Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Consensus revenue estimates increase by 16%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates upgraded to US$4.94 loss, revenue downgraded

First quarter 2023 earnings released: US$1.22 loss per share (vs US$1.51 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$10.00

No longer forecast to breakeven

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

Price target increased to US$200

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.31 loss in 3Q 2020)

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Pulmatrix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Consensus revenue estimates increase to US$8.85m

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Second quarter 2021 earnings released: US$0.068 loss per share (vs US$0.048 loss in 2Q 2020)

Independent Director Mark Iwicki has left the company

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Consensus revenue estimates increase to US$6.45m

First quarter 2021 earnings released: US$0.089 loss per share (vs US$0.23 loss in 1Q 2020)

Independent Director has left the company

Full year 2020 earnings released: US$0.67 loss per share (vs US$1.23 loss in FY 2019)

Pulmatrix Provides Pipeline and Business Update

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

New 90-day high: US$1.84

New 90-day high: US$1.41

New 90-day high: US$1.28

Third quarter 2020 earnings released: US$0.31 loss per share

Earnings beat expectations

Price target lowered to US$10.00

Pulmatrix, Inc. Appoints Todd Bazemore to Its Board of Directors, Effective October 1, 2020

Pulmatrix, Inc. Provides an Update on Product Pipeline

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera